SCHEMBL987019

SCHEMBL987019

O=CC1CCC(OCc2ccccc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.48
OPRL1 P41146 2/20 0.48
DPP4 P27487 1/20 0.48
SIGMAR1 Q99720 2/20 0.46
CARM1 Q86X55 2/20 0.46
PRMT6 Q96LA8 2/20 0.46
TMEM97 Q5BJF2 1/20 0.46
PRMT8 Q9NR22 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSK P43235 1/20 0.45
EPHX2 P34913 1/20 0.44
BCHE P06276 1/20 0.41
PSEN1 P49768 2/20 0.39
PSEN2 P49810 2/20 0.39
APH1B Q8WW43 2/20 0.39
NCSTN Q92542 2/20 0.39
APH1A Q96BI3 2/20 0.39
PSENEN Q9NZ42 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16838885 1.00 OPRM1 (0.48) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL11998001 0.90 CTSL (0.43) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL6469380 0.85 OPRM1 (0.59) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL24899061 0.84 CTSL (0.46) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL21141929 0.84 CTSL (0.46) OPRM1OPRL1DPP4SIGMAR1CARM1
SCHEMBL16761764 0.83 CARM1 (0.48) CARM1PRMT6BCHE
SCHEMBL16762086 0.83 CARM1 (0.48) CARM1PRMT6BCHE
SCHEMBL16838881 0.83 HSD17B3 (0.39) OPRM1SIGMAR1HRH3HTR2AHTR2C
SCHEMBL16761765 0.83 CARM1 (0.48) CARM1PRMT6BCHE
SCHEMBL16761694 0.83 CARM1 (0.48) CARM1PRMT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025122832-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS GENEP INC. (US) 2025-06-12 WO disclosed
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2025-02-27 US disclosed
WO-2025037229-A1 COMPOUNDS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF ERK NOVARTIS AG (CH) 2025-02-20 WO disclosed
EP-4444420-A2 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
CN-116802182-A Pyrazolopyridine derivatives and uses thereof 诺华股份有限公司 2023-09-22 CN disclosed
WO-2023107723-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed
CN-110997871-A Liquid crystal compounds 默克专利股份有限公司 2020-04-10 CN disclosed
WO-2019034588-A1 LIQUID-CRYSTALLINE COMPOUNDS MERCK PATENT GMBH (DE) 2019-02-21 WO disclosed
WO-2019034588-A1 LIQUID-CRYSTALLINE COMPOUNDS MERCK PATENT GMBH (DE) 2019-02-21 WO disclosed
US-9550793-B2 Spirocyclic compounds, compositions and medicinal applications thereof ADVINUS THERAPEUTICS LIMITED (IN) 2017-01-24 US disclosed
US-20150218187-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF IMPETIS BIOSCIENCES LTD. (IN) 2015-08-06 US disclosed
US-8791303-B2 Herbicides SYNGENTA LIMITED (GB) 2014-07-29 US disclosed
US-8791303-B2 Herbicides SYNGENTA LIMITED (GB) 2014-07-29 US disclosed
US-8791303-B2 Herbicides SYNGENTA LIMITED (GB) 2014-07-29 US disclosed
US-20120178623-A1 NOVEL HERBICIDES SYNGENTA CROP PROTECTION LLC (US) 2012-07-12 US disclosed
US-20120178623-A1 NOVEL HERBICIDES SYNGENTA CROP PROTECTION LLC (US) 2012-07-12 US disclosed
US-20120178623-A1 NOVEL HERBICIDES SYNGENTA CROP PROTECTION LLC (US) 2012-07-12 US disclosed
EP-2454223-A1 HERBICIDALLY ACTIVE 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE DERIVATIVES Syngenta Limited (GB) 2012-05-23 EP disclosed
WO-2011007146-A1 HERBICIDALLY ACTIVE 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE DERIVATIVES SYNGENTA LIMITED (GB) 2011-01-20 WO disclosed
WO-2011007146-A1 HERBICIDALLY ACTIVE 2-(SUBSTITUTED-PHENYL)-CYCLOPENTANE-1,3-DIONE DERIVATIVES SYNGENTA LIMITED (GB) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218187-A1 SPIROCYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF DGAT1, DGAT2, CPT1A OPRM1 2065/4885OPRL1 1971/4885DPP4 1463/4885
US-20120178623-A1 NOVEL HERBICIDES DDT, CBR3, C9 OPRM1 872/4885OPRL1 1215/4885DPP4 1526/4885
US-20250066349-A1 CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS DYRK2, DYRK1A, PYGB OPRM1 1812/4885OPRL1 1416/4885DPP4 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.